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Abstract
Background: Neuroinflammation occurs after seizures and is implicated in epileptogenesis. CCR2
is a chemokine receptor for CCL2 and their interaction mediates monocyte infiltration in the
neuroinflammatory cascade triggered in different brain pathologies. In this work CCR2 and CCL2
expression were examined following status epilepticus (SE) induced by pilocarpine injection.
Methods: SE was induced by pilocarpine injection. Control rats were injected with saline instead
of pilocarpine. Five days after SE, CCR2 staining in neurons and glial cells was examined using
imunohistochemical analyses. The number of CCR2 positive cells was determined using stereology
probes in the hippocampus. CCL2 expression in the hippocampus was examined by molecular
assay.
Results: Increased CCR2 was observed in the hippocampus after SE. Seizures also resulted in
alterations to the cell types expressing CCR2. Increased numbers of neurons that expressed CCR2
was observed following SE. Microglial cells were more closely apposed to the CCR2-labeled cells
in SE rats. In addition, rats that experienced SE exhibited CCR2-labeling in populations of
hypertrophied astrocytes, especially in CA1 and dentate gyrus. These CCR2+ astroctytes were not
observed in control rats. Examination of CCL2 expression showed that it was elevated in the
hippocampus following SE.
Conclusion: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after
pilocarpine-induced SE. Seizures also result in changes to CCR2 receptor expression in neurons
and astrocytes. These changes might be involved in detrimental neuroplasticity and
neuroinflammatory changes that occur following seizures.
Background
Chemokines are chemotactic cytokines that direct the
migration of cells that express the appropriate chemokine
receptor. Chemokine C-C motif ligand 2 (CCL2) is a
potent attractant protein for monocytes, therefore being
previously denominated monocyte chemoattractant pro-
tein-1 (MCP-1). The biological effects of CCL2 are medi-
ated via interactions with its receptor, chemokine C-C
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receptor and has also been designated as CD192, CC-
CKR-2; CKR2; CMKBR2; MCP-1-R. Upon binding to
CCR2, CCL2 regulates the migration and infiltration of
monocytes, T-lymphocytes and natural killer cells to
regions of inflammation [1-3]. Studies using CCL2 and
CCR2 knockout mice have shown that this ligand-recep-
tor complex is involved in mononuclear cell infiltration at
sites of inflammation [4-7].
In the CNS of several different species including humans,
CCR2 expression has been demonstrated in endothelial
cells, astrocytes, microglia and neurons [8-14]. In addi-
tion, CCL2 and CCR2 expressing cells are observed in
multiple brain regions including the hippocampus
[11,12] and the expression patterns of CCR2 are altered in
human neuropathological conditions. These conditions
include: multiple sclerosis [15,16], HIV encephalopathy
[17,18], Alzheimer's disease [19,20] and epilepsy [21].
Thus, CCL2 and CCR2 are expressed by several cell types
throughout the CNS and this expression is altered in con-
ditions of neuroinflammation.
Neuroinflammation occurs after seizures and may con-
tribute to a pro-epileptogenic neural system [22,23]. This
is especially true in the hippocampus, where inflamma-
tion has been shown to contribute to neuroplastic
changes that may have detrimental consequences [24,25].
However, alterations to the expression patterns of CCL2
and CCR2 have not been examined following status epi-
lepticus (SE) in a rat experimental model. Such data could
contribute greatly to our understanding of this compo-
nent of the neuroinflammatory response following an ini-
tial precipitating injury such as SE. Thus, this study
investigated whether CCL2 or CCR2 expression is altered
in the hippocampus following pilocarpine-induced SE.
The results show that both CCR2 and CCL2 are increased
in the hippocampus following seizures. In addition, it was
observed that seizures result in neuroplastic changes to
the cell numbers and types that express CCR2.
Methods
All experimental procedures were approved by the IACUC
of the Texas A&M University Health Science Center and
the Scott & White Hospital. Animals were housed 2 per
cage and maintained in a 12 hour light-dark cycle (06:00-
18:00) with food and water provided ad libitum.
Pilocarpine-induced seizures
Adult Sprague Dawley rats (230-235 g) were treated with
methyl-scopolamine (1 mg/kg i.p.; Sigma) 30 min before
pilocarpine hydrochloride i.p. injection (320 mg/kg;
Sigma). Animal behavior was observed and the onset of
SE was considered when animals exhibited a Racine class
3 seizure [26], that lasted more than 5 minutes and pro-
gressed to uncontrollable stage 5 seizures. Ninety minutes
after SE onset diazepam i.p. (10 mg/kg; Sigma) was
administrated to stop seizures. Only animals that pre-
sented at least stage 5 seizures based on Racine's scale [26]
were included in the SE group (n = 10). Control rats (n =
10) received the same treatment but were injected with
saline instead of pilocarpine. Five days after seizure induc-
tion rats were sacrificed for analysis.
Immunohistochemistry
For immunohistochemical analysis, animals (n = 4 per
group) were deeply anesthetized with Euthasol (pento-
barbital sodium and phenytoin sodium; 175 mg/kg, i.p.)
and transcardially perfused with 4% paraformaldehyde in
phosphate buffer. The brains were removed, postfixed for
24 hours and cryoprotected in sucrose solution. Forty μm
thick sections were cut using a cryostat (Microm HM 505
E) and were processed for immunohistochemistry with
anti- CCR2 (rabbit anti-CCR2, 1:200; Abcam). The anti-
body specificity was verified by omitting the primary
CCR2 antibody and also by blocking of CCR2 antibody
with the CCR2 peptide (Abcam) that was used as an
immunogen for the antibody production.
Double-labeling immunohistochemistry
In order to decipher the cell types that express CCR2, dou-
ble-labeling immunohistochemistry was performed using
the following antibodies combined with CCR2 staining:
neuronal nuclei protein (mouse anti-NeuN, 1:1000;
Chemicon) that stains neurons; microtubule-associated
protein 2 (mouse anti-MAP-2, 1:1000; Millipore), a neu-
ron-specific microtubule protein; glial fibrillary acidic
protein (mouse anti-GFAP-Cy3, 1:500; Sigma), a marker
of astrocytes; ionized calcium binding adaptor molecule 1
(goat anti-Iba1, 1:500; Abcam) that stains macrophage/
microglia and a marker of endothelial cells (mouse anti-
ICAM-1, 1:200, R&D Systems). Tissue processing for
immunohistochemistry was performed as previously
described [27]. Briefly, sections were incubated in 0.5%
H2O2 for 30 min and 1% H2O2 for 1 hr, followed by PBS
(0.1 M, pH 7.4) rinsing. Nonspecific staining was blocked
by incubating the tissue for 1 hr in 3% normal goat serum
(Vector Labs), in PBS. Sections were next incubated in pri-
mary antibodies, in PBS with 3% normal goat serum and
0.05% Tween-20, rotating for 48 hr, at 4°C. Sections were
then washed in PBS and incubated with secondary fluo-
rescent antibodies (Alexa 488 and 555, 1:200; Millipore),
rotating at RT for 90 min. The tissue was next rinsed in
PBS baths. It should be noted that the anti-GFAP (Sigma)
is conjugated to CY3, thus no secondary antibody was
used. It should also be noted that for the anti-Iba1 reac-
tion, normal horse serum (3%; Vector Labs) was used
instead of normal goat serum. Brain sections were then
mounted onto glass slides and coverslips were applied
with hard set mounting medium with DAPI (4',6-diamid-Page 2 of 11
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ization.
Confocal images
All immuno-labeling was verified using a laser scanning
confocal microscope (Olympus Fluoview 1000). The
sequential scanning feature was used to ensure that cross-
excitation did not occur. The 3-D confocal images were
processed and analyzed with FV10-ASW (version 1.7a)
software. To confirm double-labeling of CCR2 with NeuN
and GFAP, quantitative co-localization analyses were
employed using the Pearson's correlation coefficient,
overlap coefficient and co-localization coefficients M1
and M2. Pearson's correlation coefficient is used to
describe the correlation of the intensity variation between
channels. Overlap coefficient indicates the intersecting
volume of the signals. The co-localization coefficients M1
and M2 indicate the contribution of one color channel in
the co-localized area. In this study M1 represent a contri-
bution of CCR2, while M2 show a contribution of NeuN
or GFAP. In order to generate the co-localization coeffi-
cients the regions of interest of each image were selected
and the average of the result of each slice that composed
the final image was used.
Stereology of NeuN/CCR2 double-labeled cells
Once staining was verified using the confocal microscope,
the number of cells expressing CCR2 was estimated using
the optical dissector method [28]. Analysis was performed
in different hippocampal regions using a microscope
(Nikon Eclipse MU) with a motorized stage connected to
a computer running the Stereo Investigator software (MBF
Bioscience). Briefly, the dentate gyrus, and hippocampal
areas CA1 and CA3 were examined in 5 sections per rat.
For the dentate gyrus tracing, molecular and granular lay-
ers were delineated together and are referred as ML/GCL
in the text. Preliminary population estimates were per-
formed. Based on these population estimates, a counting
frame of 100 × 100 μm was distributed in a randomly
positioned lattice of 200 × 200 μm. CCR2 positive
(CCR2+) cells were counted using as criteria staining in
defined round cell bodies. Cellular processes were not
considered for stereological counting. In addition to
CCR2-labeled cells, the number of CCR2/NeuN double-
labeled cells was also counted within the same counting
frame. Results were statistically analyzed using a t-test and
are presented as density of cells/mm3 ± SEM.
Distance between Iba1 and CCR2+ cells
The 3-D images of microglia cells stained with Iba1 and
CCR2 + cells were captured as described in the section
"Confocal images". Using the Olympus FV10-ASW (ver-
sion 1.7a) software, the CCR2+ cell body and the cell
body of the closest Iba1+ cell were traced using the Free
Area tool. Using the Line tool, a line was traced between
the closest drawn borders of the two cell bodies. The
Measurement command calculated the length of the line
traced indicating the distance between the CCR2+ cell and
microglia in μm. Results were statistically analyzed using
Mann-Whitney Rank Sum Test and are presented as mean
distance (μm) ± SEM.
CCL2 assay
Animals (n = 6 per group) were deeply anesthetized and
then decapitated. The brain was quickly removed from the
skull and the hippocampus and cerebellum were dissected
and immediately frozen in methylbutane in dry ice. CCL2
tissue levels were assayed against a standard curve pro-
vided by the Milliplex MAP kit (Millipore) and was per-
formed per manufacturer instructions. Briefly, 25 μl of
standard, control or a tissue homogenate sample was
added to 25 μl assay buffer. To this solution, 25 μl of
beads were added and the reaction was allowed to pro-
ceed overnight at 4°C. The beads were washed twice with
wash buffer and incubated with 25 μl of detection anti-
body at RT for 2 hrs, followed by the addition of 25 μl of
Streptavidin-Phycoerythrin compound and allowed to
incubate 30 min at RT. The beads were then washed twice
with wash buffer and incubated with 150 μl of Sheath
Fluid for 5 min at RT. The fluorescence intensity was
measured on the Luminex machine (Millipore, 100 μl, 50
beads per bead set) and the analyte concentration was
determined using the BioRad software (BioPlex Manager
version 5.0). The assay was run in triplicate to confirm the
results. The tissue concentration of CCL2 was normalized
to the total protein concentration and presented as pg/μg
of total protein ± SEM.
Results
Increased CCR2 and CCL2 in the hippocampus after SE
In normal adult rats, the CCR2 immunohistochemical
analysis revealed a sparse distribution of cells expressing
CCR2 in the hippocampus. In rats that experienced SE,
although still sparse, there were significantly more cells
labeled with CCR2 (Figure 1). These cells were character-
ized mainly by punctate staining of cell bodies with lim-
ited staining over proximal processes. In addition to
increased cell body staining in SE rats, CCR2 labeling was
observed in isolated processes that appeared to have
either a neuronal or glial phenotype (Figure 1). This pat-
tern of staining was most robust in the dentate gyrus and
CA1 region of the hippocampus. Control rats exhibited
similar cell body staining, but rarely presented isolated
stained processes. Any visible staining was eliminated
when the primary antibody was omitted or was conju-
gated with the CCR2 peptide (data not shown).
Quantitative stereological analysis showed that rats with
SE have a significantly increased expression of CCR2 in
hippocampal CA1 compared with control rats (p = 0.003,Page 3 of 11
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showed a significant increase (p = 0.001) in the expres-
sion of CCL2 in the hippocampus of SE rats compared
with control animals (Figure 1). There was no change in
the CCL2 expression in the cerebellum (Figure 1). This
region was used as a control area because it is not greatly
affected relative to limbic structures by pilocarpine-
induced seizures.
Neuronal CCR2 expression in the hippocampus after 
seizures
Double-labeling immunohistochemistry revealed CCR2+
cells that co-label for NeuN-labeled neurons (Figure 2).
The CCR2 staining appeared punctiform and predomi-
nantly localized to the surface of the neuron cell body.
Since NeuN primarily stains the nucleus of the neuron
and to a lesser extent labels the peripheral cytoplasm and
proximal processes, the co-localization coefficients were
not very robust in these double-labeled preparations
(Table 1). Stereological quantification revealed a signifi-
cant increase in the density of CCR2/NeuN double-
labeled cells in CA1 of SE rats (p = 0.029, Figure 3). Fur-
ther analyses showed that almost all (> 99%) CCR2-
expressing cells were double-labeled with NeuN in the
molecular and granule cell layers of the dentate gyrus and
CA1 region of the hippocampus in control animals. Alter-
natively, in SE rats, this percentage significantly decreased
to approximately 80% of CCR2-labeled cells that co-label
CCR2 and CCL2 expression in the hippocampusFigure 1
CCR2 and CCL2 expression in the hippocampus. Confocal micrographs showing CCR2 staining in control (A) and SE 
(B) rats. Note that both control and SE rats presented a similar punctate staining pattern of cell bodies (arrows). In addition to 
cell body staining, SE rats presented numerous isolated processes labeled with CCR2 (arrowheads). (C) Graph of the mean 
density of CCR2-labeled cell bodies showing that the density of CCR2 labeled cells in SE rats was significantly increased (mean 
± SEM, **p < 0.01, t-test) in hippocampal CA1 when compared with control rats. (D) Graph of the mean CCL2 protein 
expression in the hippocampus showing significantly increased (mean ± SEM, **p < 0.01, t-test) CCL2 expression compared to 
control rats. Note that there was no change in CCL2 expression in the cerebellum, a region where monocyte infiltration is not 
expected after SE. Scale bar = 20 μm.Page 4 of 11
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Confocal micrographs of CCR2 and NeuN double-labeling in hippocampal CA1Figure 2
Confocal micrographs of CCR2 and NeuN double-labeling in hippocampal CA1. As can be seen in C and F, CCR2 is 
observed as punctate staining patterns in the peri-neuronal cytoplasm of cell bodies (arrows) in the pyramidal cell layer (PCL) 
and in stratum radiatum (SR). In addition, the proximal processes of the neurons from SE rats (F) were occasionally observed 
to label with CCR2 (arrowheads). The cell marked with the asterisk is enlarged in the inset to depict this pattern of labeling 
(F). Note that compared to control rats (A, C), there was a greater number of CCR2/NeuN double-labeled cells in SE rats (D, 
F). Scale bar: 20 μm.
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examination of the neuronal population expressing CCR2
showed a sub-population of MAP-2 labeled cell bodies
that also expressed CCR2 (Figure 4). However, MAP-2
labeled neuronal processes were rarely found to double-
label with CCR2 (Figure 4).
Glial cell expression of CCR2 in the hippocampus after 
seizures
In addition to the neuronal localization of CCR2, the SE
rats had a population of non-neuronal processes labeled
for CCR2. These processes were primarily observed in hip-
pocampal area CA1, as well as in the dentate gyrus. Such
a robust labeling was not observed in the control rats.
Double-labeling immunohistochemistry with anti-GFAP
demonstrated that the majority of these CCR2-labeled
processes from SE rats were astrocytic (Figure 5). These
double-labeled astrocytic processes often appeared hyper-
trophied (Figure 5). In the dentate gyrus, some of the
CCR2-labeled astrocytic processes were the radial glial
processes that extend through the granule cell layer and
this pattern of labeling was more pronounced in the SE
rats. In addition, a relatively robust population of CCR2-
labeled astrocytic processes were orientated into the hilus
(Figure 5). Such processes were not observed in the con-
trol group. The high co-localization coefficients presented
in Table 1 confirm the extent of CCR2 and GFAP double-
labeling in CA1 and dentate gyrus of SE rats.
Relationship between microglia and CCR2-expressing cells
Double-labeling with the microglial cell marker Iba1 and
CCR2 did not reveal CCR2/Iba-1 double labeling in either
the control or SE rats (data not shown). A significant dif-
ference was found in the relationship of the proximity
between microglial cells and CCR2-labeled cells following
SE, such that the microglial cells are more closely apposed
to the CCR2-labeled cells. In fact, in some cases, micro-
glial cells appeared to be engulfing the CCR2+ cells (Fig-
ure 6). On the other hand, in control animals, there were
less microglial cells and these cells did not exhibit an acti-
vated morphology that was seen in SE rats. The decrease
in the distance between CCR2+ cell and the closest micro-
glia cell was significant in CA1, CA3, hilus, and in the ML/
GCL of the dentate gyrus in SE rats when compared with
control rats (p ≤ 0.001 in all regions; Figure 6).
CCR2-expressing cells and endothelial cells
In addition to the neuronal and glial characterization of
CCR2 expressing cells, the double immunohistochemistry
for CCR2 and ICAM-1, showed that a small population of
Stereological analysis of CCR2-labeled neurons in the hip-pocampusFigure 3
Stereological analysis of CCR2-labeled neurons in the 
hippocampus. (A) The density of CCR2/NeuN double-
labeled cells in different regions of the hippocampus. Note 
that SE rats had a significantly (mean ± SEM, *p < 0.05, t-test) 
increased density of CCR2/NeuN double-labeled cells in 
CA1when compared with control rats. Although the graphs 
appear to show a trend towards an increased density of 
CCR2/NeuN in the other hippocampal regions, none of 
them approached significance. (B) Graph depicting the mean 
proportion of CCR2+ cells that were co-labeled with NeuN. 
Following SE, the proportion of CCR2-labeled cells that dou-
ble-label for NeuN was significantly (mean ± SEM, *p < 0.05, 
t-test) decreased in the molecular layer and granular cell 
layer (ML/GCL) of the dentate gyrus and CA1 region of the 
hippocampus. This suggests that other cell types are induced 
to express CCR2 following seizures.
Confocal micrographs of double-labeling for CCR2 and MAP2 in CA1Figure 4
Confocal micrographs of double-labeling for CCR2 
and MAP2 in CA1. This figure shows CCR2 expression in 
the cell body that co-localizes with MAP2 (arrow). Alterna-
tively, the isolated CCR2 processes (arrowhead) were not 
co-labeled with MAP-2, suggesting that they are not neuro-
nal. Scale bar: 20 μm.Page 6 of 11
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Table 1: Colocalization coefficients.
Region Double-labeled cells Animal Pearson's Coeff. Overlap Coloc. M1 Coloc. M2
CA1*a CCR2/NeuN Control 0,28 0,56 0,04 0,04
CCR2/NeuN SE 0,29 0,46 0,13 0,13
CA1*b CCR2/GFAP Control 0,04 0,72 0,00 0,00
CCR2/GFAP SE 0,74 0,78 0,74 0,71
DG *b CCR2/GFAP Control 0,03 0,05 0,00 0,00
CCR2/GFAP SE 0,59 0,72 0,61 0,47
*a, related to Figure 2. *b, related to Figure 5. DG, dentate gyrus.
Confocal micrographs of double-labeling for CCR2 and GFAP in dentate gyrus and CA1Figure 5
Confocal micrographs of double-labeling for CCR2 and GFAP in dentate gyrus and CA1. In the dentate gyrus of SE 
rats (D-F) the double-labeling is present in the radial processes that extend through the granular cell layer (white arrowheads 
in F). In addition, a relatively large population of CCR2-labeled astrocytes is oriented toward the hilus (white arrows in F). 
Alternatively, control rats (A-C) presented CCR2 staining only in the cell body (black arrow in C). This labeling pattern is also 
observed in SE rats (black arrows in F). In the CA1region of SE rats (J-L) there is a robust co-localization of CCR2 and GFAP in 
many astrocytes (black arrowheads in L). Note that many of these double-labeled astrocytes have a hypertrophied appearance. 
In the CA1 region of control rats (G-I), the CCR2 labeling is very limited, being restricted to the cell body (black arrow in I). 
CCR2 staining in cell bodies (black arrows) of control and SE rats was not observed to co-localize with GFAP. Scale bar: den-
tate gyrus, 40 μm; CA1, 20 μm.
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Confocal micrographs of double-labeling for CCR2 and Iba1 in the hippocampusFigure 6
Confocal micrographs of double-labeling for CCR2 and Iba1 in the hippocampus. In control rats (A-C), microglia 
cells (arrowheads) in the hippocampus do not present a clear relationship with CCR2+ cells (arrow). On the other hand, rats 
that experienced SE (E-F) shows many microglial cells (arrowheads) that appear activated and are closely apposed to CCR2-
labeled cells (arrow). (G) Graph of the distance between CCR2+ and Iba1+ cells. Note that compared to controls, SE rats 
present a significant decrease in the distance between these two cells types, with the mean distance being less than a few 
micrometers (mean ± SEM, **p ≤ 0.001, Mann-Whitney Rank Sum Test). Scale bar: 20 μm.
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lial cell marker ICAM-1 in SE rats (Figure 7). Additionally,
in the SE rats, CCR2+ cells were more frequently observed
juxtaposed with endothelial cells, in the perivascular
regions, relative to controls (Figure 7).
Discussion
The results of the present study show that CCR2 and CCL2
are increased in the hippocampus following pilocarpine-
induced seizures. These data also demonstrate that sei-
zures result in selective changes to the cell types that
express CCR2. Analysis of the cell types expressing CCR2
shows that SE rats had an increased density of NeuN-
labeled neurons expressing CCR2, compared to control
rats. However, the fraction of CCR2-labeled cells that dou-
ble-labeled for NeuN in control rats was almost 100%,
compared to about 80% in SE rats. Therefore, in addition
to the increased neuronal CCR2 expression, other cell
types are induced to express CCR2 following seizures.
It seems that GFAP-labeled astrocytes, more specifically
their processes, are a major source of increased CCR2
labeling in the hippocampus following SE. This data is
consistent with reports of CCR2 expression by astrocytes
in other conditions of neuroinflammation [29]. It is
important to note that CCR2 labeling in astrocytic proc-
esses was not considered for stereological cell counts and
the additional CCR2-labeled cell bodies did not appear to
be astrocytes. Therefore, other cell types might contribute
to increased cellular expression of CCR2 after seizures.
Although no Iba1/CCR2 co-labeling was observed, it is
possible that these cells might express CCR2 at different
timepoints after injury.
Increased expression of CCL2 in this study is consistent
with data from humans, showing elevated levels of CCL2
in tissue from patients with intractable epilepsy [21].
Functionally, increased CCL2 and CCR2 expression in the
hippocampus might be a mechanism to activate and
recruit inflammatory cells to this injured site after sei-
zures. It is known that that CCL2 binds to CCR2 on brain
endothelial cells and contributes to increased brain
endothelial permeability [30]. This increased permeabil-
ity promotes the recruitment of inflammatory cells, such
as monocytes and leukocytes at sites of inflammation
[31]. Following pilocarpine-induced SE, it was shown that
CCR2 is expressed by some endothelial and perivascular
cells. These cells partially account for the non-neuronal
increase in cellular expression of CCR2 after SE.
The close relationship between activated microglia and
CCR2-labeled cells in SE animals suggest that the chemok-
ine-receptor interaction might influence the glial reactiv-
ity. Since CCR2-labeled cell bodies presented neuronal
morphology it is possible that the microglial activity may
be related with neuronal damage following SE.
Through activation of CCR2, the chemokine CCL2 is able
to direct the movement of astrocytes [13,32]. The fact that
CCR2 expression by astrocytes was robustly observed in
CA1 and the dentate gyrus following SE, is consistent with
the idea that these regions are typically damaged after pro-
longed seizures [33-35]. The data showing CCR2 expres-
sion by hypertrophied astrocytes in the dentate gyrus
following seizures is of particular interest because previ-
ous studies have shown astrocyte and microglial activa-
tion in the dentate gyrus at the same 5 day timepoint
following pilocarpine-induced seizures [27]. In addition,
previous studies have shown that after SE, hilar basal den-
drites from immature neurons aberrantly grow along an
ectopic glial scaffold into the hilus [36]. The astrocytic
processes that contribute to the ectopic glial scaffold [36]
were observed to be in a similar location as the CCR2-
labeled astrocytic processes in this study. It is pertinent to
note that the hilar basal dendrites that grow along these
astrocytic processes are integrated into an aberrant circuit
Confocal micrographs of double-labeling for CCR2 and ICAM-1 in the hippocampusFigure 7
Confocal micrographs of double-labeling for CCR2 and ICAM-1 in the hippocampus. In control rats (A-C) some 
CCR2+ cells (arrow) were identified in the perivascular region (labeled in red). In SE animals (D-F), similar CCR2+ cells in the 
perivascular region (arrows) seem to be more frequent than in control animals. In addition, co-localization of CCR2 and ICAM-
1was occasionally observed in SE animals (arrowheads, G-I). Scale bar: 20 μm.Page 9 of 11
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astrocytic CCR2 may be involved in mediating neuroplas-
tic changes to newly generated neurons and their associ-
ated astrocytes following seizures.
Consistent with the notion that CCR2 may play a role in
adult neurogenesis are the data showing neural progenitor
cells in the adult brain that express CCR2 [40,41]. It is
thought that this expression is involved in directing
migration of neuronal progenitor cells to sites of neuroin-
flammation [42,43]. Interestingly, ectopic migration of
newborn neurons into the hilus is another seizure-
induced neuroplastic change that contributes to a hyper-
excitable circuitry [39,44,45]. Thus, it is plausible that
increased CCL2 and CCR2 expression in the dentate gyrus
are involved in pro-epileptogenic, neurogenic alterations.
Future experiments using knockout mice and/or pharma-
cological manipulations will be needed to test this
hypothesis.
Conclusions
In conclusion, this study shows increased expression of
CCL2 and CCR2 in the hippocampus following seizures.
The results also demonstrate that CCR2 is preferentially
increased in neurons and astrocytic processes after SE. In
light of the existing literature suggesting an inflammatory
role in epileptogenesis, the data suggest that this chemok-
ine-receptor interaction might be involved in the epilep-
togenic progression. Future studies should examine the
effect of manipulating this chemokine/receptor complex
and its effect on seizures.
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